Outlined lime-green document icon with lines of text on a dark background, beside the weekly news headline.

Nicotine pouch news: eight EU ministers want national pouch bans — 11 October 2026

Posted on

Eight EU health ministers wrote to the Commission on 6 October asking to be allowed to ban nicotine pouches outright in their own countries. It is a political letter, not a law, and it was widely overstated — but it is signed, dated and specific, and the cross-border-sales ask in it would matter more to readers here than the ban.

A week with one real document in it and a great deal of noise around it. Four items below are anchored to primary sources; a fifth is American non-news, which this week is the story; and a closing section lists what circulated without any document behind it at all.

Eight ministers ask Brussels to let member states ban pouches

The letter is four pages, dated 6 October 2026, addressed to Health Commissioner Olivér Várhelyi, sent by the Dutch Ministry of Health, Welfare and Sport under reference 4421352-1100363-VGP, and published through the Dutch government’s own open-government portal. It is signed by Sophie Hermans of the Netherlands, on her own behalf and that of the health ministers of Belgium, Finland, France, Hungary, Latvia, Slovenia and Spain. Its subject is the revision of the Tobacco Products Directive and the Tobacco Advertising Directive.

It has a section headed “Nicotine pouches”, and that section is unambiguous. “Oral tobacco (snus) has been banned since 1992 in the EU”, it begins, and pouches “are strikingly similar to oral tobacco and can be seen as a circumvention of the oral tobacco ban”. It calls them “highly harmful and addictive, though marketed with unfounded claims related to smoking cessation”. The ask: “we call for the reinforcement of the EU wide oral tobacco ban and therefore call for Member States to be allowed to adopt strict national measures, including a total ban on nicotine pouches”.

The part I would actually watch is in a different section. Under “Cross border distance sales” the ministers say national measures “are increasingly undermined by online sales and cross-border trade, including from third countries”, and call on the Commission to “effectively address the banning of cross-border distance sales within the EU”. Elsewhere the letter asks for a “market freeze” so that no new nicotine-containing product can enter the EU market, for “strict maximum nicotine levels across all products”, for “a broad flavour ban for all products”, for plain packaging, and for the phasing out of “nicotine dependence across the European Union”.

Now the corrections, because almost every write-up got at least one of these wrong. This is not an EU-wide pouch ban: the request is for permission for individual member states to ban, which is a subsidiarity argument and the opposite of harmonised prohibition. It is not a Council position or a Commission document — it is eight of twenty-seven ministers, one letter, legally binding on nobody. The “market freeze” is about products that have not yet entered the market, not the ones on sale. And the letter itself confirms how early this is: the ministers “welcome the European Commission’s initiative to revise the TPD and TAD”, meaning no legislative proposal exists yet.

Two of the signatories already ban pouches outright, and a third has the strictest content cap in the Union: Latvia allows a maximum of four milligrams of nicotine per gram, upheld by its Constitutional Court last October. That is the company this letter keeps.

Ireland raises tobacco excise and leaves pouches out of the budget entirely

Ireland’s Budget 2027 was delivered on 6 October. The Department of Finance’s own Tax Policy Changes document records that “Excise duty on tobacco products is being increased by 1 euro, inclusive of VAT, on a pack of 20 cigarettes in the most popular price category, together with pro rata increases for other tobacco products” — given statutory effect by a budget-night financial resolution. The vaping increase is separate and later: “Excise duty on all e-liquid products is being increased by 20 cents per millilitre, exclusive of VAT with effect from 1 January 2027”, taking the total to 70 cents a millilitre.

The sourced negative is the point. I searched all forty-one pages: the words “nicotine” and “pouch” appear zero times. Ireland has no pouch-specific excise category, and the budget did not create one. Readers of the 4 October issue will recognise the pattern from the UK — a vape-liquid duty that pouches sit outside. Two countries, two budgets, the same gap.

Britain counts smokers and vapers, and still does not count pouch users

The Office for National Statistics published Adult smoking habits in the UK: 2025 on 6 October. “Around 4.9 million people aged 18 years and over (9.8% of the population) smoked cigarettes in the UK in 2025”, and “around 5.4 million adults aged 16 years and over (9.9%) used an e-cigarette daily or occasionally” — the second consecutive year in which “the percentage of current e-cigarette users continued to be higher than current smokers”.

Again the absence is the news: the words “nicotine pouch”, “pouches”, “snus” and “oral nicotine” appear nowhere in the bulletin. Three weeks from now, on 29 October, section 10 of the Tobacco and Vapes Act 2026 makes it an offence to sell a vaping or nicotine product to anyone under 18 in the UK — a commencement separate from the generational tobacco provisions, which section 175(3) holds back to 1 January 2027. Britain is about to regulate the age of sale for a product its flagship prevalence statistic does not measure.

Imperial Brands names its pouch brands and publishes no pouch numbers

The only financial document from a tobacco major in the window was Imperial Brands’ FY26 pre-close trading update of 8 October: “On track to deliver full-year guidance for FY26 on all metrics; £1.5 billion share buyback for FY27”. On oral nicotine it says that “in modern oral our existing portfolio of growing brands, including Zone and Skruf, has been enhanced by the acquisitions of Black Buffalo in the US and Helwit in Sweden.”

That is the whole of it. No modern-oral volume, no modern-oral revenue, no mention of the phrase “nicotine pouch” at all, and the double-digit growth figure being quoted elsewhere is a forward-looking expectation for next-generation products as a group, not a reported result. Useful as a statement of intent — four pouch brands now sit inside one company — and useless as a market datapoint.

In America, nothing moved, and a watchdog explains why

I re-read the FDA’s authorised list today. It still says “There are 43 nicotine pouch products authorized by the FDA”, content current as of 21 August 2026 — unchanged for seven weeks. No new authorisations, no denials, no Center for Tobacco Products warning letters issued or posted in the window, and no tobacco or nicotine rulemaking in the Federal Register.

The Government Accountability Office published the explanation four days before this week began, and it circulated during it. Tobacco Products: FDA Should Monitor Timeliness of Application Reviews (published 30 September, released 1 October) found that of the applications FDA has received, “almost 132 thousand remained without a completed review as of December 31, 2025”, and that “FDA took an average of 507 days to complete its review of tobacco product applications”. GAO’s recommendation is procedural — that FDA “collect the data necessary to monitor whether it is meeting its timeliness goals”. Nothing in it is a new policy, and the as-of date is nine months old. But it is the machinery behind a list that has not grown since August.

Reported this week, with no document behind it

Four stories ran widely and I could not stand any of them up, which is worth saying rather than quietly omitting.

  • Portugal’s parliament “debated its nicotine pouch bill on 7 October”. The bill is real — Proposta de Lei 84/XVII/1, authorising the government to set a legal regime for nicotine pouches. But the parliamentary record shows no event on 7, 8 or 9 October. The last recorded steps are both 30 September: a health committee vote carried “Aprovado por unanimidade”, and dispatch of the report to the President of the Assembly. The defensible fact is the committee’s unanimous approval on 30 September, not a plenary debate.
  • The Philippines “now requires safety certification for nicotine pouches”. A trade-press account gives a Department of Trade and Industry order number and a September signing date. Missing: the order text, on the department’s or the standards bureau’s own site, and an effective date, which no account states. Even if confirmed, a September signing is not a this-week event.
  • India “has banned nicotine pouches as unapproved drugs”. No circular number, no gazette notification, and the accounts themselves place the directive in September.
  • US retail figures showing modern oral up 24.7% to $7.53bn and 55.3% of smokeless. These come from a commercial retail-scan vendor via a trade newsletter, measured over 52 weeks to 9 August. Not a regulator, not a company filing, not a study, and not a this-week measurement.

Also circulating, and worth flagging as recycled: several outlets ran “US FDA authorizes lower-risk claim for 20 ZYN pouches” this week. That order was issued on 30 June 2026 and is four months old.

One honest gap in my own checking. The EU’s technical-regulation notification system — where draft national pouch rules are filed, and the single best early-warning source this column has — would not return a date-bounded listing this week; individual notifications resolved, the search did not. So I cannot confirm or exclude a new draft national rule filed between 5 and 11 October. The Official Journal for the same week was also unreachable. Everywhere else I checked and have named published nothing.

Sources

Previous issues: 4 October, 27 September and 20 September. Standing reference: the global nicotine pouch regulation tracker and the global map.

Nicotine is addictive. No tobacco or nicotine product is safe, and completely stopping is the lowest-risk option. This site is for adults who already use nicotine — 21+ in the United States, 18+ or your local legal age elsewhere. Nothing here is medical advice.